Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

NIH 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 3Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Oropharyngeal Neoplasms 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Colorectal Neoplasms 5Cholangiocarcinoma 5Carcinoma 5Biliary Tract Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Squamous Cell 4Mesothelioma, Malignant 3Laryngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Non-squamous Non-small Cell Lung Cancer 2

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Cisplatin 5pembrolizumab 4durvalumab 4Carboplatin 4cemiplimab 3Radiation 3Platinum 3Paclitaxel 3Cetuximab 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3cabozantinib 2atezolizumab 2Radiotherapy 2Pemetrexed 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2ALT-803 2130-nm albumin-bound paclitaxel 2zipalertinib 1repotrectinib 1poly ICLC 1ipatasertib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Carcinoma × Cisplatin × 30 days × Clear all
NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06312137 2026-05-22

TroFuse-019

Merck Sharp & Dohme LLC

Phase 3 Recruiting
780 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05172245 2026-05-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
46 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡